Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

55.89 +1.72 (+3.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 257,630
Open 54.60
Bid (Size) 52.00 (17)
Ask (Size) 57.50 (1)
Prev. Close 54.17
Today's Range 53.64 - 56.13
52wk Range 31.42 - 58.26
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery
Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial. 
Via Benzinga
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta
Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates. 
Via Benzinga
Topics Bankruptcy

Performance

YTD
+4.3%
+4.3%
1 Month
+0.3%
+0.3%
3 Month
+43.6%
+43.6%
6 Month
+32.0%
+32.0%
1 Year
+15.0%
+15.0%

More News

Read More
Signet Posts Upbeat Earnings, Joins Ferguson Enterprises, Dollar General And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Tuesday's session: gap up and gap down stocks
Via Chartmill
MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover
Via Investor's Business Daily
Tuesday's pre-market session: top gainers and losers
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report
Via Benzinga
Topics Intellectual Property
Why Credo Technology Group Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
US Stocks Likely To Open Lower: Expert Highlights Technical Analysis Showing S&P 500's 'Recovery Is Real' And Not A 'Bull Trap' Or 'Bear Market Rally'
Via Benzinga
Topics Stocks
Dollar General, Signet Jewelers And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
This West Pharmaceutical Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely?
Via Stocktwits
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MLTX Stock Earnings: MoonLake Misses EPS for Q1 2024
Via InvestorPlace
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
From Komodo Health
Via Business Wire
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test
Via Investor's Business Daily
Why Is Inflammatory Disease-Focused MoonLake Immunotherapeutics Stock Trading Higher Today?
Via Benzinga
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks

Frequently Asked Questions

Is MoonLake Immunotherapeutics - Class A Ordinary Shares publicly traded?
Yes, MoonLake Immunotherapeutics - Class A Ordinary Shares is publicly traded.
What exchange does MoonLake Immunotherapeutics - Class A Ordinary Shares trade on?
MoonLake Immunotherapeutics - Class A Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for MoonLake Immunotherapeutics - Class A Ordinary Shares?
The ticker symbol for MoonLake Immunotherapeutics - Class A Ordinary Shares is MLTX on the Nasdaq Stock Market
What is the current price of MoonLake Immunotherapeutics - Class A Ordinary Shares?
The current price of MoonLake Immunotherapeutics - Class A Ordinary Shares is 55.89
When was MoonLake Immunotherapeutics - Class A Ordinary Shares last traded?
The last trade of MoonLake Immunotherapeutics - Class A Ordinary Shares was at 08/22/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.